Care patterns and outcomes for adults diagnosed with ovarian cancer since January 2021

Ovarian Cancer Epidemiology and Care in Brazil: A Multicenter Perspective (OLIVIA Study) Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

This project will see if collecting clinical, treatment, and outcome information from adults diagnosed with ovarian cancer since January 2021 can reveal patterns in care and outcomes.

Quick facts

• Study type: Observational
• Enrollment: 250 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: AstraZeneca (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Porto Alegre)
• Trial ID: NCT07167433 on ClinicalTrials.gov

What this trial studies

This is a bi-directional observational project that will collect retrospective and prospective data on 250 adults diagnosed with ovarian cancer (stages IA–IVB) or with persistent/recurrent disease from January 2021. Baseline sociodemographic, clinical, pathological, and genetic testing/counseling data will be recorded at enrollment. Follow-up information on treatments and outcomes will be gathered at 12, 24, and 36 months to capture short- and long-term patterns. The goal is to identify strengths and weaknesses in current surgical, systemic, HIPEC, and referral practices to inform quality parameters for care.

Who should consider this trial

Good fit: Adults aged 18 or older with a diagnosis of ovarian cancer (stages IA–IVB) or persistent/recurrent disease from January 2021 onward, any histology, who are treated at participating centers are eligible.

Not a fit: Patients with borderline ovarian tumors, pregnant patients, those with a synchronous tumor or second primary in the past five years (except thyroid cancer and non-melanoma skin cancer), and people under 18 are excluded and will not benefit from participation.

Why it matters

Potential benefit: If successful, the findings could highlight care gaps and support the development of quality standards that improve treatment decisions, surgical care, genetic referrals, and patient outcomes.

How similar studies have performed: Other observational registries and real-world data projects in ovarian cancer have identified practice gaps and informed quality-improvement efforts, although they do not test treatments directly.

Eligibility criteria

Inclusion Criteria:

* Patients ≥18 years old;
* Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
* Irrespective of histology

Exclusion Criteria:

* Borderline tumors;
* Pregnancy;
* Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);

Where this trial is running

Porto Alegre

• Research Site — Porto Alegre, Brazil (Recruiting)

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center

Conditions Ovarian Cancer